Dudediligence.

Madrigal Pharmaceuticals, Inc

MDGLNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$62.2MSep ’24$103.3MDec ’24$137.3MMar ’25$212.8MJun ’25$287.3MSep ’25$321.1MDec ’25$311.3MMar ’26$364.3MJun ’26
Net income, by quarter
−$107.0MSep ’24−$59.4MDec ’24−$73.2MMar ’25−$42.3MJun ’25−$114.2MSep ’25−$58.6MDec ’25−$94.4MMar ’26−$57.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$0.00$0.00$180.1M$958.4M
Gross profitnone on file$0.00$0.00$173.9Mnone on file
Operating income−$242.5M−$293.6M−$380.5M−$497.9M−$300.1M
Net income−$241.8M−$295.4M−$373.6M−$465.9M−$288.3M
Operating cash flow−$183.9M−$224.9M−$324.2M−$455.6M−$189.6M
Free cash flow−$184.1M−$225.1M−$325.7M−$457.0M−$190.0M
Cash$36.3M$331.5M$99.9M$100.0M$198.7M
Debt$0.00$49.3M$115.5M$117.6M$339.9M
Shares outstanding17.1M18.1M19.9M22.0M22.8M